Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD 1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies

Next Previous
Search
Trial Profile

A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD 1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemiplimab (Primary) ; Carboplatin; Cyclophosphamides; Docetaxel; Granulocyte macrophage colony stimulating factor; Paclitaxel; Pemetrexed
  • Indications Adenocarcinoma; Carcinoma; Cervical cancer; Head and neck cancer; Liver cancer; Neuroendocrine carcinoma; Non-small cell lung cancer; Skin cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals; Sanofi

    • Most Recent Events

    • 01 Sep 2021 Primary endpoint has not been met (HNSCC expansion cohort: safety, tolerability, and dose-limiting toxicities of cemiplimab in combination with RT, cyclophosphamide, and GM-CSF) , according to Results published in the Oncologist
    • 01 Sep 2021 Results (n=15) from expansion cohort3 of a dose-escalation phase of this trial in Head and neck cancers patients with advanced malignancies published in the Oncologist
    • 25 Mar 2021 Results assessing fixed dose of cemiplimab in patients with advanced malignancies using population pharmacokinetics (PopPK) modeling and simulations, published in the Advances in Therapy.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top